TY - JOUR
T1 - Advances and issues in mantle cell lymphoma research
T2 - Report of the 2014 Mantle Cell Lymphoma Consortium Workshop
AU - Kahl, Brad S.
AU - Gordon, Leo I.
AU - Dreyling, Martin
AU - Gascoyne, Randy D.
AU - Sotomayor, Eduardo M.
N1 - Publisher Copyright:
© 2015 Informa UK, Ltd.
PY - 2015/9/2
Y1 - 2015/9/2
N2 - Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma characterized by the t(11;14) chromosomal translocation and cyclin D1 over-expression. A biologically and clinically heterogeneous lymphoma, MCL, remains clinically challenging, with no proven curative therapy and no established standard of care. However, there have been considerable advances in the last several years in the treatment and understanding of MCL with the FDA approval of lenalidomide and ibrutinib, the development of other potentially active novel agents and the identification of recurrent mutations through new genomic sequencing approaches that may contribute to the biology of MCL and to therapeutic resistance. At the Lymphoma Research Foundation's 11th MCL Workshop, researchers gathered to discuss recent studies and current issues related to the biology of MCL, novel therapeutic targets and new treatment strategies. The presentations are summarized in this manuscript, which is intended to highlight areas of active investigation and identify topics for future research.
AB - Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma characterized by the t(11;14) chromosomal translocation and cyclin D1 over-expression. A biologically and clinically heterogeneous lymphoma, MCL, remains clinically challenging, with no proven curative therapy and no established standard of care. However, there have been considerable advances in the last several years in the treatment and understanding of MCL with the FDA approval of lenalidomide and ibrutinib, the development of other potentially active novel agents and the identification of recurrent mutations through new genomic sequencing approaches that may contribute to the biology of MCL and to therapeutic resistance. At the Lymphoma Research Foundation's 11th MCL Workshop, researchers gathered to discuss recent studies and current issues related to the biology of MCL, novel therapeutic targets and new treatment strategies. The presentations are summarized in this manuscript, which is intended to highlight areas of active investigation and identify topics for future research.
KW - Lymphoma and Hodgkin's disease
KW - immunotherapy
KW - marrow and stem cell transplantation clinical results
KW - pharmacotherapeutics
UR - http://www.scopus.com/inward/record.url?scp=84946043477&partnerID=8YFLogxK
U2 - 10.3109/10428194.2015.1045903
DO - 10.3109/10428194.2015.1045903
M3 - Review article
C2 - 25944379
AN - SCOPUS:84946043477
SN - 1042-8194
VL - 56
SP - 2505
EP - 2511
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 9
ER -